Drill (Drill)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceTetracaine + ChlorhexidineTetracaine + Chlorhexidine
Similar drugsTo uncover
  • Drill
    lozenges
    Pierre Fabre Medication Production     France
    • Dosage form: & nbsppastilles [no sugar]
    Composition:

    1 loaf of 2.5 grams contains:

    Active substances:

    Tetracaine hydrochloride 0.200 mg

    Chlorhexidine Bigluconate 3,000 mg

    Excipients:

    Ascorbic acid 52,500 mg

    Ammonium glycyrrhizinate 5,000 mg

    Aspartame 1,000 mg

    Isomalt 2424.250 mg

    Flavor 1 * 9.550 mg

    Flavor 2 ** 4.525 mg

    Note:

    * Ingredients: alcoholic raspberry extract, black currant, raspberry, cherry, vanilla, concentrated fruit juices, benzaldehyde, vanillin, lactic acid, maltol. ** Ingredients: racemtol, thymol, terpineol, eucalyptus essential oil.

    Description:

    Semi-transparent pastilles of round shape.

    Pharmacotherapeutic group:antiseptic + local anesthetic
    ATX: & nbsp

    R.02.A   Drugs for the treatment of throat diseases

    R.02.A.A.20   Other drugs

    Pharmacodynamics:

    The combined preparation has an antiseptic and an anesthetic effect when applied topically in the ENT. The chlorhexidine incorporated into the preparation has an antimicrobial effect against a wide spectrum Gram-positive and gram-negative microorganisms, lipophilic viruses. Besides.it also has an antifungal effect (active against yeast fungi).

    The tetracaine included in the preparation has a peripheral local anesthetic effect on the receptors of the mucous membrane of the oral cavity and pharynx, which provides an anesthetic effect.

    Pharmacokinetics:

    Hiorgexedin

    When resorbing the lozenge chlorhexidine gradually released into saliva, binds to the surface of the oral mucosa, is absorbed by tooth enamel, dentin and dental cement, and then again slowly released into saliva. It is defined in saliva for 8-12 hours. due to its cationic nature, chlorhexidine firmly binds to the mucosa and other tissues, which is why it is very poorly absorbed. Part of the drug can be swallowed with saliva. After contact with the mucosa chlorhexidine absorbed into organic structures, which ensures its long-term local effect and prevents the release of the drug itself into the systemic circulation, the blood is detected highly low concentration. It is distributed mainly to the kidneys and liver,is poorly metabolized and is excreted unchanged with feces (99.5% of the dose inside).

    Tetracaine

    With resorption lozenges tetracaine quickly absorbed and moderately binds with plasma proteins (76%). is metabolized in the liver to para-amiobenzoic acid.

    Indications:Infectious inflammatory diseases of the oral cavity and pharynx, not accompanied by fever, the formation of aphthus or violation of the integrity of the mucous membrane of the mouth and pharynx.
    Contraindications:

    - Hypersensitivity to any components of the drug.

    - Allergic reactions to local anesthetics and chlorhexidine in the anamnesis.

    - Children under 6 years.

    - Phenylketonuria (the drug contains aspartame).

    Carefully:
    Pregnancy and lactation:There are limited data on Drill pregnancy, data on the penetration of the drug into breast milk are absent. Therefore, it is recommended to refrain from using the drug during pregnancy and breastfeeding.
    Dosing and Administration:

    The lozenge resorbing, but not swallowing, is kept in the mouth until completely dissolved. The duration of Drill should not exceed 5 days.

    Between the methods of the drug should be observed interval of at least 2 hours. After taking the drug is not recommended: take food and drinks, as well as brush your teeth for the next 1-2 hours.

    Adults and children over 15 years of age 1 lozenge 4 times a day. The maximum daily dose is 4 lozenges.

    Children from 6 to 15 years 1 lozenges 2-3 times a day. The maximum daily dose is 3 lozenges.

    Side effects:

    Adverse reactions are systematized according to system-organic classes and listed in accordance with the following gradation:

    very often (> 1/10),

    often (> 1/100 to <1/10),

    infrequently (> 1/1000 to < 1/100),

    rarely (> 1/10000 to <1/1000),

    very rarely (<1/10000)

    frequency is unknown (can not be estimated from available data).

    Immune system disorders:

    frequency unknown: allergic reactions, anaphylactic reactions, anaphylactic shock, hypersensitivity reactions.

    General disorders and disorders at the site of administration:

    frequency is unknown: a temporary loss of sensitivity of the tongue and pharynx can cause a disruption in swallowing with the risk of suffocation.

    Disturbances from the gastrointestinal tract:

    frequency unknown: transient staining of the tongue, teeth and composite filling material in brown color.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

    Overdose:

    Symptoms:

    In case of severe overdose the following effects are observed: disturbances in the function of the gastrointestinal tract (nausea, vomiting, diarrhea), local irritation (throat, esophagus), nervous system disorders (nervousness, visual impairment, convulsions), cardiovascular system (lowering of blood pressure, bradycardia, ventricular arrhythmia , methemoglobinemia.

    Treatment: symptomatic.

    Interaction:

    It is necessary to avoid simultaneous or sequential administration of Drill and other antiseptics (especially anionic substances, such as lauryl sulfate) due to the probability of interaction leading to antagonism, inactivation and other manifestations of such interaction.

    Special instructions:Do not use the drug before eating or drinking. Because of anesthetics in the area of ​​the oropharyngeal department, problems with swallowing are possible (a temporary loss of sensitivity of the tongue and pharynx can cause the ingress of a nipple or fluid into the windpipe,as a result of which there is a risk of suffocation), therefore it is necessary to give this medication with care to children from 6 to 12 years. After taking the drug is not recommended to eat and drink, as well as brushing your teeth for the next 1-2 hours. Long-term use (more than 5 days) of the drug is undesirable because of a possible violation normal composition microflora of the oral cavity and pharynx with the risk of bacterial or fungal infection. Repeated or prolonged exposure to the mucosa may result in a risk of systemic toxic effects due to mucosal contact with anesthetics (violations function central nervous system with the development of seizures, suppression of cardiovascular function system).

    In case of deterioration / absence of improvement of state of health after 5 days or occurrence of adverse reactions recommended discontinue treatment and turn to to the doctor.

    Dyeing of teeth or composite filling material is unstable and can be prevented to a great extent by daily tooth brushing with usual toothpaste, and in the case of dentures using traditional cleaning products. The preparation contains aspartame and contraindicated patients from phenylketonuria.

    Effect on the ability to drive transp. cf. and fur:

    Drill is not affected or has little effect on the ability to drive a car and other mechanical means.

    Form release / dosage:

    Pastilles [without sugar]. For 12 pastilles in a blister of PVC / PVDC / aluminum foil. For 1 or 2 blisters with instructions for use in a pack of cardboard.

    Packaging:(12) - blister (2) / 12 lozenges in a PVC / PVDC blister and aluminum foil; 2 blisters in a cardboard box with instructions for use / - cardboard pack
    Storage conditions:

    In a dry place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    3 years

    Do not use after the expiry date indicated on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:П N013172 / 01
    Date of registration:18.08.2011
    The owner of the registration certificate:Pierre Fabre Medication ProductionPierre Fabre Medication Production France
    Manufacturer: & nbsp
    Representation: & nbspPIER FABR PIER FABR France
    Information update date: & nbsp26.09.2015
    Illustrated instructions
      Instructions
      Up